Skip to main content

Table 4 Incidence of hypoglycemia (percent patients) stratified by monotherapy and add-on therapies

From: Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus

 

Placebo

Dapagliflozin

5 mg

10 mg

Placebo-controlled studies

7.0

10.9

10.2

Monotherapy studies

2.0

2.2

2.9

Add-on combination plus metformin

3.1

–

3.1

Plus pioglitazone

0.7

2.1

0

Plus a sulfonylurea

4.8

6.9

7.3

Plus insulin

35.0

45.3

42.3

  1. Pooled data from 12 placebo-controlled phase II/III clinical studies. Data from Ptaszynska et al. [71]
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840